Together with the anti-oxidative and anti-apoptotic action of the HO products BR and CO exploited by tumor cells, these findings suggest HO-1 inhibition as a suitable therapy against different cancer types [55], such as melanoma [58], prostate cancer cells [59], as well as various leukemia malignancies [60,61]. Here, HMOX1 is linked to neoplasm.